Literature DB >> 29865056

Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

Einar M Sigurdsson1.   

Abstract

Tau immunotherapies have now advanced from proof-of-concept studies to Phase II clinical trials. This review briefly outlines developments in the field and discusses how these therapies may work, which involves multiple variables that are connected in complex ways. These various factors are likely to define therapeutic success in humans and have not been thoroughly investigated, at least based on published reports.

Entities:  

Keywords:  Alzheimer’s disease; antibodies; clinical trials; immunotherapies; mechanisms; tau; tauopathy

Mesh：

Substances：

Year:  2018        PMID： 29865056      PMCID： PMC6171771          DOI： 10.3233/JAD-179937

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN： 1387-2877            Impact factor:   4.472


  72 in total

1.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

2.  Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.

Authors:  Chloe K Nobuhara; Sarah L DeVos; Caitlin Commins; Susanne Wegmann; Benjamin D Moore; Allyson D Roe; Isabel Costantino; Matthew P Frosch; Rose Pitstick; George A Carlson; Christoph Hock; Roger M Nitsch; Fabio Montrasio; Jan Grimm; Anne E Cheung; Anthone W Dunah; Marion Wittmann; Thierry Bussiere; Paul H Weinreb; Bradley T Hyman; Shuko Takeda
Journal:  Am J Pathol       Date:  2017-04-11       Impact factor: 4.307

3.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

4.  Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.

Authors:  Wencheng Liu; Lingzhi Zhao; Brittany Blackman; Mayur Parmar; Man Ying Wong; Thomas Woo; Fangmin Yu; Maria J Chiuchiolo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Steven M Paul
Journal:  J Neurosci       Date:  2016-12-07       Impact factor: 6.167

5.  Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.

Authors:  Kiran Yanamandra; Tirth K Patel; Hong Jiang; Suzanne Schindler; Jason D Ulrich; Adam L Boxer; Bruce L Miller; Diana R Kerwin; Gilbert Gallardo; Floy Stewart; Mary Beth Finn; Nigel J Cairns; Philip B Verghese; Ilana Fogelman; Tim West; Joel Braunstein; Grace Robinson; Jennifer Keyser; Joseph Roh; Stephanie S Knapik; Yan Hu; David M Holtzman
Journal:  Sci Transl Med       Date:  2017-04-19       Impact factor: 17.956

6.  p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.

Authors:  Ken C Walls; Rahasson R Ager; Vitaly Vasilevko; Dave Cheng; Rodrigo Medeiros; Frank M LaFerla
Journal:  Neurosci Lett       Date:  2014-06-02       Impact factor: 3.046

Review 7.  Tau Immunotherapy.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2015-11-10       Impact factor: 2.977

8.  Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.

Authors:  Asami Kondo; Koorosh Shahpasand; Rebekah Mannix; Jianhua Qiu; Juliet Moncaster; Chun-Hau Chen; Yandan Yao; Yu-Min Lin; Jane A Driver; Yan Sun; Shuo Wei; Man-Li Luo; Onder Albayram; Pengyu Huang; Alexander Rotenberg; Akihide Ryo; Lee E Goldstein; Alvaro Pascual-Leone; Ann C McKee; William Meehan; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nature       Date:  2015-07-15       Impact factor: 49.962

9.  Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.

Authors:  Wenjie Luo; Wencheng Liu; Xiaoyan Hu; Mary Hanna; April Caravaca; Steven M Paul
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

10.  Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.

Authors:  Clara Theunis; Natalia Crespo-Biel; Valérie Gafner; Maria Pihlgren; María Pilar López-Deber; Pedro Reis; David T Hickman; Oskar Adolfsson; Nathalie Chuard; Dorin Mlaki Ndao; Peter Borghgraef; Herman Devijver; Fred Van Leuven; Andrea Pfeifer; Andreas Muhs
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240
View more
  13 in total

Review 1.  Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

Authors:  Senthilkumar Krishnaswamy; Huai-Wei Huang; Isabella S Marchal; Hyung Don Ryoo; Einar M Sigurdsson
Journal:  Neurobiol Dis       Date:  2020-01-23       Impact factor: 5.996

2.  Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.

Authors:  Crystal M Vander Zanden; Eva Y Chi
Journal:  J Pharm Sci       Date:  2019-10-21       Impact factor: 3.534

Review 3.  The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors:  Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal:  Neuromolecular Med       Date:  2019-01-17       Impact factor: 3.843

4.  Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein.

Authors:  Jessica E Chukwu; Erin E Congdon; Einar M Sigurdsson; Xiang-Peng Kong
Journal:  MAbs       Date:  2019-02-26       Impact factor: 5.857

Review 5.  A walk through tau therapeutic strategies.

Authors:  Santosh Jadhav; Jesus Avila; Michael Schöll; Gabor G Kovacs; Enikö Kövari; Rostislav Skrabana; Lewis D Evans; Eva Kontsekova; Barbara Malawska; Rohan de Silva; Luc Buee; Norbert Zilka
Journal:  Acta Neuropathol Commun       Date:  2019-02-15       Impact factor: 7.801

6.  Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment.

Authors:  Min Liu; Manish D Paranjpe; Xin Zhou; Phan Q Duy; Manu S Goyal; Tammie L S Benzinger; Jie Lu; Rongfu Wang; Yun Zhou
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 7.  Advances and considerations in AD tau-targeted immunotherapy.

Authors:  Alice Bittar; Nemil Bhatt; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2019-12-10       Impact factor: 5.996

8.  In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice.

Authors:  Eliot J Davidowitz; Pavan K Krishnamurthy; Patricia Lopez; Heidy Jimenez; Leslie Adrien; Peter Davies; James G Moe
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 9.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431

Review 10.  Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors:  Steven S Plotkin; Neil R Cashman
Journal:  Neurobiol Dis       Date:  2020-07-16       Impact factor: 7.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.